Abstract
When treating advanced thyroid cancer cases with Lenvatinib, most of these patients are old and we sometimes hesitate to administer the drug to elderly cases. We have experienced administering low-dose Lenvatinib to aging patients who were over 80 years old. The first case was a 92-year-old man. He was administered 10mg of Lenvatinib at the outpatient clinic, could continue the treatment without serious side effects, and maintained PR for one year. The second case was an 86-year-old female. She had an obstructed airway due to tumor invasion. Due to her poor general condition, we decided to start with 4 mg of Lenvatinib. The trachea-invading tumor shrank, and she was able to stay at home, but eventually died when the tumor progressed. Low-dose Lenvatinib administration was shown to be tolerated and to reduce side effects even in the elderly. This treatment, however, may have insufficient antitumor effects. The organ function, social status, and living environment of older adults are varied, so we should decide the administration dose and method according to the condition of each case.
| Original language | English |
|---|---|
| Pages (from-to) | 46-50 |
| Number of pages | 5 |
| Journal | Japanese Journal of Head and Neck Cancer |
| Volume | 44 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2018 Jan 1 |
Fingerprint
Keywords
- Elderly patients
- Hyroid cancer
- Lenvatinib
ASJC Scopus subject areas
- Otorhinolaryngology
- Oncology
Cite this
Lenvatinib administration for elderly patients (over 80 years old) with advanced thyroid cancer. / Ozawa, Hiroyuki; Sekimizu, Mariko; Ito, Fumihiro; Ikari, Yuichi; Nakahara, Nana; Saito, Shin; Yoshihama, Keisuke; Ogawa, Kaoru.
In: Japanese Journal of Head and Neck Cancer, Vol. 44, No. 1, 01.01.2018, p. 46-50.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lenvatinib administration for elderly patients (over 80 years old) with advanced thyroid cancer
AU - Ozawa, Hiroyuki
AU - Sekimizu, Mariko
AU - Ito, Fumihiro
AU - Ikari, Yuichi
AU - Nakahara, Nana
AU - Saito, Shin
AU - Yoshihama, Keisuke
AU - Ogawa, Kaoru
PY - 2018/1/1
Y1 - 2018/1/1
N2 - When treating advanced thyroid cancer cases with Lenvatinib, most of these patients are old and we sometimes hesitate to administer the drug to elderly cases. We have experienced administering low-dose Lenvatinib to aging patients who were over 80 years old. The first case was a 92-year-old man. He was administered 10mg of Lenvatinib at the outpatient clinic, could continue the treatment without serious side effects, and maintained PR for one year. The second case was an 86-year-old female. She had an obstructed airway due to tumor invasion. Due to her poor general condition, we decided to start with 4 mg of Lenvatinib. The trachea-invading tumor shrank, and she was able to stay at home, but eventually died when the tumor progressed. Low-dose Lenvatinib administration was shown to be tolerated and to reduce side effects even in the elderly. This treatment, however, may have insufficient antitumor effects. The organ function, social status, and living environment of older adults are varied, so we should decide the administration dose and method according to the condition of each case.
AB - When treating advanced thyroid cancer cases with Lenvatinib, most of these patients are old and we sometimes hesitate to administer the drug to elderly cases. We have experienced administering low-dose Lenvatinib to aging patients who were over 80 years old. The first case was a 92-year-old man. He was administered 10mg of Lenvatinib at the outpatient clinic, could continue the treatment without serious side effects, and maintained PR for one year. The second case was an 86-year-old female. She had an obstructed airway due to tumor invasion. Due to her poor general condition, we decided to start with 4 mg of Lenvatinib. The trachea-invading tumor shrank, and she was able to stay at home, but eventually died when the tumor progressed. Low-dose Lenvatinib administration was shown to be tolerated and to reduce side effects even in the elderly. This treatment, however, may have insufficient antitumor effects. The organ function, social status, and living environment of older adults are varied, so we should decide the administration dose and method according to the condition of each case.
KW - Elderly patients
KW - Hyroid cancer
KW - Lenvatinib
UR - http://www.scopus.com/inward/record.url?scp=85051248336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051248336&partnerID=8YFLogxK
U2 - 10.5981/jjhnc.44.46
DO - 10.5981/jjhnc.44.46
M3 - Article
VL - 44
SP - 46
EP - 50
JO - Japanese Journal of Head and Neck Cancer
JF - Japanese Journal of Head and Neck Cancer
SN - 1349-5747
IS - 1
ER -